Unique avidity driven mechanism engages CD3 on T cells when binding either two or three tumor-associated antigens to enhance selectivity for AML cells Preclinical data demonstrated that MP0533 can selectively target and kill both leukemic blast cells and stem cells, while sparing healthy cells

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR :  Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics,

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer,

New data indicates potential to expand the therapeutic window and improve safety compared to existing T-cell engagers Tri-specific T-cell engager resulted in AML cell-specific cytotoxicity with minimal off-tumor toxicity Phase I clinical trial evaluating safety and dose of MP0533 in patients with

First clinical observation of tumor localized CD40 activation provided by MP0317 No systemic or dose-limiting toxicities observed, a key parameter for CD40 agents Dose escalation remains ongoing with study recruitment anticipated to complete in 1H 2023 ZURICH-SCHLIEREN, Switzerland and CONCORD,

- Company will also host a reception with Key Opinion Leaders in New Orleans - ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) --   Molecular Partners AG  (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG  (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the team will present at

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR : Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR : Molecular Partners AG  (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics,

Continued development of MP0317, with initial clinical data from Phase 1 study expected in the second half of 2022 Initiation of Phase 1 study for MP0533 expected by year end Continued progression of proprietary DARPin-conjugated radioligand therapeutics; innate immune cell engagers;